AVC-201 is a CRISPR-engineered allogeneic switchable CAR-T candidate designed to target and eliminate cells expressing receptor CD123, which is known to be overexpressed in nearly all acute myeloid leukemias, and several other hematological malignancies.
'Patients with AML with minimal residual disease or who progress after currently available treatment approaches generally have a very poor prognosis and limited options,' said Professor
The phase 1 study, which includes up to 37 patients, will be conducted at multiple sites in
'We are excited to build on the safety and promising activity observed in our ongoing autologous switchable clinical study in AML (AVC-101) by now implementing what we believe is the most scientifically-compelling allogeneic technology in the industry,' said
About AVC-201
AVC-201 is a CRISPR-edited Chimeric Antigen Receptor ('CAR')-T Cell therapy that embodies two discrete technology platforms. The first leverages AvenCell's '
About AVC-201 Clinical Program
AvenCell's Phase I study (NCT05949125) is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AVC-201 in adults with relapsed or refractory AML and other CD123 positive hematological malignancies. The study is an open-label, single-ascending dose design used to identify two dose levels of AVC-201 that will be further evaluated in a subsequent Phase 2 study.
About Acute Myeloid Leukemia (AML)
AVC-201 is a CRISPR-edited Chimeric Antigen Receptor ('CAR')-T Cell therapy that embodies two discrete technology platforms. The first leverages AvenCell's '
About AVC-201 Clinical Program
AvenCell's Phase I study (NCT05949125) is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AVC-201 in adults with relapsed or refractory AML and other CD123 positive hematological malignancies. The study is an open-label, single-ascending dose design used to identify a cell and targeting module dose level combination of AVC-201 that will be further evaluated in a subsequent Phase 2 study.
About Acute Myeloid Leukemia (AML)
AML typically develops from mutations in the DNA of early blood-forming cells, leading to the disruption of normal cell maturation and proliferation. This results in a buildup of immature cells in the bone marrow, crowding out healthy cells and impairing their ability to function properly. AML accounts for a significant proportion of all leukemia cases. Approximately 21,000 new cases of AML are diagnosed in
About AvenCell Therapeutics
AvenCell derives its name from the French word 'avenir' to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and prostate cancer, and additional programs targeting other hematological malignancies and solid tumors. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches.
Forward-Looking Statements
This press release contains 'forward-looking statements' of
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including AvenCell's ability to initiate, progress or complete pre-clinical or clinical studies within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional pre-clinical or clinical studies; uncertainties relating to regulatory applications and related filing and approval timelines; risks related to AvenCell's relationships and collaborations with third parties; risks related to the maintenance and protection of AvenCell's intellectual property; risks related to the potential successful development and commercialization of AvenCell's product candidates and risks associated with AvenCell's understanding of cell therapy and its application to the treatment of cancers.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to AvenCell, and AvenCell assumes no obligation and disclaims any intent to update any such forward-looking statements.
Contact:
Tel: +49 351 44664500
Email: info@avencell.com
(C) 2024 Electronic News Publishing, source